Akari Therapeutics Plc advances AKTX-101 as RNA splicing ADC targets TROP2 resistance in oncology
Discover how AKTX-101 could redefine TROP2 ADC resistance strategies in oncology. Read the full analysis now.
Pharma & Biotech
Pharma & Biotech
Ferring wins ADSTILADRIN label update as operational efficiency becomes a bigger oncology battleground
FDA clears faster ADSTILADRIN thawing for bladder cancer care. Read why this workflow update could matter for NMIBC adoption and treatment strategy.
Pharma & Biotech
Gene therapy gains ground in bladder cancer as NCCN strengthens Ferring Pharmaceuticals’ ADSTILADRIN recommendation
ADSTILADRIN gains NCCN upgrade in bladder cancer. Discover what this means for gene therapy adoption, clinical use, and future NMIBC treatment trends.
Pharma & Biotech
Macau clears ImmunityBio’s ANKTIVA for BCG-unresponsive NMIBC, opening Asia market amid commercialization test
ImmunityBio's first Asia approval for ANKTIVA in BCG-unresponsive bladder cancer: what the Macau clearance means for its global strategy. Read the analysis.